TDB-DST Backs Commercial Rollout of Indigenous Renal Diagnostic ‘Proflo-U’
Government signs pact with Prantae Solutions to scale point-of-care kidney testing across India.
The Technology Development Board (TDB) under the Department of Science & Technology (DST) has signed a commercialization agreement with Prantae Solutions Pvt Ltd.
The partnership aims to bring “Proflo-U,” an indigenous point-of-care renal diagnostic platform, into the commercial marketplace.
The goal: expand access to timely kidney function assessment across India.
- Indigenous diagnostic technology
- Portable and cost-effective platform
- Focus on nationwide availability
From Lab to Market
The agreement supports the transition of Proflo-U from development to large-scale deployment.
TDB’s backing is designed to accelerate market entry and wider adoption.
The device enables kidney evaluation in diverse settings — both within and beyond traditional healthcare facilities.
- Supports decentralized testing
- Expands reach beyond hospitals
- Improves early-stage assessment
In a country where distance often delays diagnosis, portability changes the equation.
Strengthening India’s Health Innovation Ecosystem
The collaboration aligns with the government’s broader objective of building a robust indigenous healthcare innovation ecosystem.
TDB’s support reflects a push to scale low-cost diagnostics developed in India.
The focus extends beyond commercialization.
- Promote homegrown medical technology
- Improve clinical outcomes
- Reduce dependency on imported solutions
Early detection remains critical for individuals at risk of kidney complications.
Timely testing can mean the difference between manageable intervention and advanced disease.
Faster Diagnosis at the Point of Care
Proflo-U enables quick and accurate kidney function testing at the point of care.
Clinicians can diagnose renal impairment earlier and initiate treatment without delay.
That immediacy strengthens frontline healthcare delivery.
- Rapid, on-site testing
- Early clinical intervention
- Improved patient management
The tool reduces reliance on centralized laboratory infrastructure, particularly in rural and semi-urban regions.
For public health systems, that translates into lower logistical burden and faster service delivery.
Supporting Universal Healthcare Goals
The partnership also signals continued emphasis on industry–academia collaboration and indigenous R&D.
As India expands access to preventive diagnostics, tools like Proflo-U can support early disease detection and better patient outcomes.
- Enhanced preventive care
- Reduced health disparities
- Progress toward universal healthcare access
Can decentralized diagnostics redefine how India manages chronic disease?
The TDB-Prantae agreement suggests policymakers see point-of-care innovation as central to the next phase of healthcare delivery reform.
TL;DR: TDB-DST has signed an agreement with Prantae Solutions to commercialize “Proflo-U,” an indigenous point-of-care renal diagnostic device. The portable, low-cost platform aims to improve early kidney disease detection, expand rural access, reduce reliance on centralized labs, and strengthen India’s healthcare innovation ecosystem.
AI summary:
- TDB partners with Prantae Solutions
- Commercial rollout of Proflo-U renal diagnostic
- Portable, low-cost point-of-care testing
- Boost for rural and semi-urban healthcare
- Supports indigenous health innovation








